302 related articles for article (PubMed ID: 22448149)
1. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
Turner EH; Knoepflmacher D; Shapley L
PLoS Med; 2012; 9(3):e1001189. PubMed ID: 22448149
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Melnik T; Soares BG; Puga ME; Atallah AN
Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
Schneider LS; Dagerman K; Insel PS
Am J Geriatr Psychiatry; 2006 Mar; 14(3):191-210. PubMed ID: 16505124
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
Lorenz RA; Jackson CW; Saitz M
Pharmacotherapy; 2010 Sep; 30(9):942-51. PubMed ID: 20795849
[TBL] [Abstract][Full Text] [Related]
8. Switching antipsychotic medications: not enough, too often, or just right?
Weiden PJ
Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
[No Abstract] [Full Text] [Related]
9. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
10. Second-generation antipsychotics for major depressive disorder and dysthymia.
Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
[TBL] [Abstract][Full Text] [Related]
11. Akathisia and second-generation antipsychotic drugs.
Kumar R; Sachdev PS
Curr Opin Psychiatry; 2009 May; 22(3):293-99. PubMed ID: 19378382
[TBL] [Abstract][Full Text] [Related]
12. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Wang PS; Schneeweiss S; Setoguchi S; Patrick A; Avorn J; Mogun H; Choudhry NK; Brookhart MA
J Clin Psychopharmacol; 2007 Dec; 27(6):707-10. PubMed ID: 18004143
[No Abstract] [Full Text] [Related]
13. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
15. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
[TBL] [Abstract][Full Text] [Related]
16. Second-generation antipsychotics cause weight gain in youths.
Harv Ment Health Lett; 2010 Jan; 26(7):7. PubMed ID: 20217902
[No Abstract] [Full Text] [Related]
17. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics for the treatment of disruptive behavior.
Lohr WD; Honaker J
Pediatr Ann; 2013 Feb; 42(2):72-7. PubMed ID: 23379410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
